Ludwig Announces Substantial Corporate Initiatives
Ludwig Enterprises, Inc. (OTC PINK:LUDG) has announced significant corporate initiatives as it prepares to launch Revealia™, its innovative cancer screening test, in 2024. The company plans to change its name to Revealia™, Inc. and apply for OTCQB listing, with aspirations for higher listings like NASDAQ or CBOE in the future. Revealia™ is positioned as the world's most convenient cancer screening test, utilizing a simple mail-order noninvasive cheek swab.
The company has collected over 3000 mRNA samples from multiple medical clinics across the US and employs proprietary machine learning AI technology for continuous statistical updates. CEO Marvin S. Hausman, MD, states that Ludwig has uncovered potentially game-changing mRNA-based genetic signals associated with cancer presence.
Ludwig Enterprises, Inc. (OTC PINK:LUDG) ha annunciato importanti iniziative aziendali mentre si prepara a lanciare Revealia™, il suo innovativo test di screening per il cancro, nel 2024. L'azienda prevede di cambiare nome in Revealia™, Inc. e richiedere una listing OTCQB, con aspirazioni per listing più elevati come NASDAQ o CBOE in futuro. Revealia™ è posizionato come il test di screening per il cancro più conveniente al mondo, utilizzando un semplice tampone guanciale non invasivo da ordinare per posta.
L'azienda ha raccolto oltre 3000 campioni di mRNA da diverse cliniche mediche negli Stati Uniti e utilizza tecnologia AI di machine learning proprietaria per aggiornamenti statistici continui. Il CEO Marvin S. Hausman, MD, afferma che Ludwig ha scoperto segnali genetici basati su mRNA che potrebbero cambiare le regole del gioco associati alla presenza di cancro.
Ludwig Enterprises, Inc. (OTC PINK:LUDG) ha anunciado iniciativas corporativas significativas mientras se prepara para lanzar Revealia™, su innovadora prueba de detección de cáncer, en 2024. La compañía planea cambiar su nombre a Revealia™, Inc. y solicitar una cotización en OTCQB, con aspiraciones a listas más altas como NASDAQ o CBOE en el futuro. Revealia™ se posiciona como la prueba de detección de cáncer más conveniente del mundo, utilizando un simple hisopo de mejilla no invasivo que se puede pedir por correo.
La empresa ha recolectado más de 3000 muestras de mRNA de múltiples clínicas médicas en los EE. UU. y utiliza tecnología de inteligencia artificial de machine learning propietaria para actualizaciones estadísticas continuas. El CEO Marvin S. Hausman, MD, declara que Ludwig ha descubierto potenciales señales genéticas basadas en mRNA asociadas con la presencia de cáncer.
Ludwig Enterprises, Inc. (OTC PINK:LUDG)는 2024년 Revealia™라는 혁신적인 암 검사 테스트를 출시할 준비를 하며 중요한 기업 이니셔티브를 발표했습니다. 이 회사는 Revealia™, Inc.로 이름을 변경할 계획이며, OTCQB 상장 신청을 할 예정입니다. 향후 NASDAQ이나 CBOE와 같은 더 높은 상장을 목표로 하고 있습니다. Revealia™는 세계에서 가장 편리한 암 검사 테스트로 자리매김하고 있으며, 간단한 우편 주문 비침습적인 뺨 면봉을 이용합니다.
이 회사는 미국 전역의 여러 의료 클리닉에서 3000개 이상의 mRNA 샘플을 수집했습니다 및 소유한 머신러닝 AI 기술을 사용하여 지속적인 통계 업데이트를 수행합니다. CEO Marvin S. Hausman, MD는 Ludwig이 암 존재와 관련된 잠재적으로 게임 체인저가 될 수 있는 mRNA 기반의 유전적 신호를 발견했다고 밝혔습니다.
Ludwig Enterprises, Inc. (OTC PINK:LUDG) a annoncé des initiatives corporatives significatives alors qu'elle se prépare à lancer Revealia™, son test de dépistage du cancer innovant, en 2024. L'entreprise prévoit de changer son nom en Revealia™, Inc. et de demander une inscription OTCQB, avec des aspirations à des inscriptions plus élevées telles que NASDAQ ou CBOE à l'avenir. Revealia™ est positionné comme le test de dépistage du cancer le plus pratique au monde, utilisant un simple écouvillon de joue non invasif en commande par courrier.
L'entreprise a collecté plus de 3000 échantillons d'ARNm provenant de multiples cliniques médicales à travers les États-Unis et utilise une technologie d'IA d'apprentissage automatique propriétaire pour des mises à jour statistiques continues. Le PDG Marvin S. Hausman, MD, déclare que Ludwig a découvert des signaux génétiques basés sur l'ARNm pouvant changer la donne en lien avec la présence de cancer.
Ludwig Enterprises, Inc. (OTC PINK:LUDG) hat bedeutende Unternehmensinitiativen angekündigt, während es sich auf die Einführung von Revealia™, seinem innovativen Krebs-Screening-Test, im Jahr 2024 vorbereitet. Das Unternehmen hat vor, seinen Namen in Revealia™, Inc. zu ändern und eine OTCQB-Listung zu beantragen, mit dem Ziel, in Zukunft höhere Listungen wie NASDAQ oder CBOE zu erreichen. Revealia™ wird als der weltweit bequemste Krebs-Screening-Test positioniert und nutzt einen einfachen, nicht-invasiven Wangenswab, der per Post bestellt werden kann.
Das Unternehmen hat über 3000 mRNA-Proben aus mehreren medizinischen Kliniken in den USA gesammelt und verwendet eigene Machine-Learning-AI-Technologie für kontinuierliche statistische Updates. CEO Marvin S. Hausman, MD, erklärt, dass Ludwig potenziell bahnbrechende mRNA-basierte genetische Signale entdeckt hat, die mit dem Vorhandensein von Krebs in Verbindung stehen.
- Planned launch of Revealia™ cancer screening test in 2024
- Intention to uplist to OTCQB, with future plans for NASDAQ or CBOE listing
- Collection of over 3000 mRNA samples for product development
- Use of proprietary machine learning AI technology for data analysis
- Potential discovery of significant mRNA-based genetic signals for cancer detection
- Current trading on OTC Pink market, which is less regulated than higher exchanges
- Pending regulatory approvals for corporate name change and new ticker symbol
- Entering a competitive market against established players like Exact Sciences
Revealia™, the world's most convenient cancer screening test, to launch in 2024
SPARKS, NV / ACCESSWIRE / August 14, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a USA-based biotechnology company, is pleased to announce its corporate vision for the next 120 days. Ludwig has embarked on a plan to reshape the Company as it nears its launch of Revealia™.
A key initiative is the change of corporate name to "Revealia™, Inc." Following regulatory approvals, the new company name and a new ticker to match the name would be in place. Revealia™ is also the name of the company's cancer screening product.
The Company intends to apply with OTCMarkets to begin trading on the OTCQB, a first step in its longer-range plan of seeking a higher listing, such as NASDAQ or CBOE.
These corporate initiatives are a direct result of the company being in a position to launch its much-anticipated cancer screening kit, Revealia™. This kit will be among the most sophisticated on the market, aiming to compete against competitors in the highly profitable genetic cancer screening market, such as Exact Sciences, which launched Cologuard in 2014, the first stool DNA test for colorectal cancer. Revealia™, the world's most convenient cancer screening test, is planned to hit the direct-to-consumer market in 2024. A simple mail-order noninvasive cheek swab can help save lives. "Ludwig has uncovered potentially game-changing mRNA-based genetic signals associated with the presence of cancer," stated Marvin S. Hausman, MD, CEO. The Company, which has collected over 3000 samples to date, continues to collect mRNA samples from over 40 multipurpose medical clinics throughout the United States. Our proprietary machine learning AI technology allows continuous statistical updates as additional patient data is received.
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc., a biotech and healthcare holding company, is a global leader in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor, and create solutions to prevent chronic inflammation, the causative agent of illnesses™ such as cancer and heart disease, which are responsible for more than
For more information please visit: http://www.ludwigent.com.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises, Inc.
Marvin S. Hausman MD, CEO
marvin@ludwigent.com
www.ludwigent.com
SOURCE: Ludwig Enterprises Inc.
View the original press release on accesswire.com
FAQ
When is Ludwig Enterprises (LUDG) planning to launch its Revealia™ cancer screening test?
What corporate changes is Ludwig Enterprises (LUDG) planning to implement?
How does Ludwig Enterprises' (LUDG) Revealia™ cancer screening test work?
How many mRNA samples has Ludwig Enterprises (LUDG) collected for its cancer screening research?
